Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
- ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
- Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Tweets from GSK
-
GSK @GSK
👋Hello from#ASH20199 in Orlando! We look forward to sharing our data, deepening current partnerships & meeting#haematologyy experts to advance our quest for more treatment options for patients.
about 19 hours ago
w -
GSK @GSK
The answer to yesterday’s poll is D: ~160,000 new cases of multiple #myeloma were diagnosed globally in 2018. New lines of therapy are needed and that’s one of the many reasons why we are working every day to improve the lives of patients. #ASH19
about 20 hours ago
-
GSK @GSK
Multiple #myeloma, a disease that arises from abnormal & uncontrolled growth of plasma cells in bone marrow, is diagnosed in 160,000 people globally each year. Chris is one of the many reasons why we’re working to improve the lives of patients living with multiple #myeloma #ASH19
about 1 day ago
